Prenatal SNP microarray analysis of over 60,000 patients: implications, importance and intriguing findings

March 17, 2020

Reproductive decisions made by balanced chromosome translocation carriers

Clinical sequencing of more than 2,500 patients with myeloid disorders using a targeted next generation sequencing platform

January 21, 2020

Genome-wide cfDNA sequencing in cancer patients

January 19, 2021

Labcorp appoints Dr. Deborah Ann Sesok-Pizzini as chief medical officer, Labcorp Diagnostics

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 19, 2021-- Labcorp , (NYSE: LH), a leading global life sciences company, announced today that Dr. Deborah Ann Sesok-Pizzini has been appointed Chief Medical Officer of Labcorp Diagnostics , following the retirement of Dr. Dot Adcock in April 2021 . Dr. Sesok-Pizzini assumed the role starting on January 11, 2021.

January 13, 2021

Media Statement: Labcorp political contributions

Labcorp does not make contributions to federal political candidates.

Managing Your Health

Diseases & Specialties

Treatment Methods & Product Testing

Lab Disciplines & Services

Prenatal SNP microarray analysis of over 60,000 patients: implications, importance and intriguing findings

Reproductive decisions made by balanced chromosome translocation carriers

Reproductive decisions made by balanced chromosome translocation carriers

Clinical sequencing of more than 2,500 patients with myeloid disorders using a targeted next generation sequencing platform

Genome-wide cfDNA sequencing in cancer patients

Genome-wide cfDNA sequencing in cancer patients

Labcorp appoints Dr. Deborah Ann Sesok-Pizzini as chief medical officer, Labcorp Diagnostics

Media Statement: Labcorp political contributions